Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Dexamethasone in Newly Diagnosed Primary ITP
NCT03252457Phase 3Unknown
- Sponsor
- Shandong University
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of decitabine in immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoint: Continuous response rate at 1 year. Status: unknown.
02
Drugs
decitabine
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03252457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252457.